Ignite Creation Date:
2024-05-06 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05847569
Status:
RECRUITING
Last Update Posted:
2023-12-11
First Post:
2023-04-27
Brief Title:
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Refractory Multiple Myeloma |
| Recurrent Multiple Myeloma |
Keywords: